ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,877 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryAllschwilBasilea Pharmaceutica AG, Allschwil
Basilea Pharmaceutica AG, Allschwil Logo
Verified· 3 sources

Basilea Pharmaceutica AG, Allschwil

Summary

About the company

Basilea Pharmaceutica AG, Allschwil is a pharmaceutical company that develops and commercializes medicines for severe and life‑threatening bacterial and fungal infections. Its portfolio includes antifungal and antibacterial products such as Cresemba (isavuconazole) and Zevtera.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
5
Development and commercialization of anti-infectives
Development and commercialization of innovative medicines in the field of anti-infectives, focusing on antifungals and antibiotics for severe infections.
Antifungal Cresemba
Intravenous and oral antifungal with Isavuconazol for the treatment of invasive aspergillosis and mucormycosis; distributed worldwide via partners.
Antibiotic Zevtera
Intravenous antibiotic with Ceftobiprole for the treatment of pneumonia, Staphylococcus aureus bacteremia, acute skin infections, and community-acquired bacterial pneumonia.
Antifungal drug candidates
Clinical antifungal candidates such as Fosmanogepix and BAL2062 for candidemia, invasive candidiasis, and invasive mould infections.
Antibiotic drug candidates
Clinical antibiotic programs such as Ceftibuten-ledaborbactam etzadroxil and BAL2420 for complicated urinary tract infections and gram-negative, multi-drug resistant bacteria.
Press

Media

March 26, 2026Media
Basilea, sales projected to triple
agefi.com
March 26, 2026Media
Basilea erwartet eine Verdreifachung des Umsatzes
agefi.com

Knowledge

No knowledge articles yet

Once Basilea Pharmaceutica AG, Allschwil has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Basilea Pharmaceutica AG, Allschwil in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Basilea Pharmaceutica AG, Allschwil by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Basilea Pharmaceutica AG, Allschwil to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hegenheimermattweg 167b
4123 Allschwil
Opening hours
Mon
08:00 - 12:00, 13:00 - 17:00
Tue
08:00 - 12:00, 13:00 - 17:00
Wed
08:00 - 12:00, 13:00 - 17:00
Thu
08:00 - 12:00, 13:00 - 17:00
Fri
08:00 - 12:00, 13:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-101.175.068
Founded
2002 · 24 years
Last commercial register change
May 7, 2026
Employees
101 to 500

Similar companies

IP
Idorsia Pharmaceuticals Ltd
Allschwil
CP
Corden Pharma Switzerland LLC
Liestal
AP
Acino Pharma AG
Liesberg
CP
Corden Pharma Fribourg AG, Zweigniederlassung Ettingen
Ettingen